The AstraZeneca PLC ADR AZN rose 1.25% to $68.81 Friday, on what proved to be an all-around positive trading session for the ...

AstraZeneca PLC closed 22.84% below its 52-week high of £133.88, which the company achieved on September 3rd.

(Reuters) -British equities closed higher on Friday, as the recent de-escalation of the global tariff war supported risk ...

AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer ...

The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn ...

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton ...

In the thriving biomedical hub of Wuxi in East China's Jiangsu province, the 2025 Taihu Bay Future Healthcare Conference ...

On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the ...

Beyond 2 years, CABG with flow assessment was associated with a higher risk for new coronary angiography and new ...

Scientists report that they have learned how certain combinations of rearranged genes can promote the progression of a rare type of kidney cancer.

Moreover, previous studies have suggested that more conservative options can be successfully used for low-risk, early-stage cervical cancer. The SHAPE trial, for example, showed that simple ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...